Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss

C4 Therapeutics ( CCCC ) reported a GAAP EPS loss of -$0.44 for 3Q25. A figure that missed analyst estimates by about $0.03. Revenue, on the other hand, came in at $11.23 million, beating expectations by $4.95 million. It's a bit of niceI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave m ...